Richard Bax MBBS, MRCGP, FRCP Lon, FRCP Edin, FFPM, FIDSA

Richard is a key TranScrip expert in Infectious Diseases and has been involved in many clinical development programmes and regulatory submissions. He has over 38 years of industry experience, including working for Glaxo, Lilly and Astra Zeneca and has developed many antibiotics and antivirals.
Richard was VP at SmithKline Beecham from 1991-1999, working in London and Philadelphia, in charge of Global Anti-infective Clinical Development, resulting in over 15 successful NDAs /MAAs and launches including Famvir/penciclovir, Bactroban and Augmentin BD. Between 2000 and 2003, Richard was Chief Scientist to Biosyn, a microbicide company based in Philadelphia.